يحاول ذهب - حر

Mideast escalation may drive correction in overvalued India stocks

June 16, 2025

|

Mint Hyderabad

FPIs are staying away due to expensive valuations. Most FPIs are awaiting a correction in India Pratik Gupta CEO & co-head, Kotak Institutional Equities

- Ram Sahgal

An escalation of hostilities in the Middle East makes India vulnerable to oil price shocks and could result in a correction in stock prices, which already seem overvalued based on earnings estimates for the current fiscal, according to Pratik Gupta, chief executive officer and co-head of Kotak Institutional Equities.

Gupta said this could cap market upside over the next few months but expects earnings to pick up in the second half of the current fiscal. Foreign portfolio investors acknowledge India's strong macros and resilience of domestic flows, but await a correction to make large fresh investments, he said.

Edited excerpts:

Nifty earnings in FY25 grew in modest single digits, reflected in market valuations correcting from October to March. Our GDP growth is slated at 6.5% and inflation at 3.7% for the current fiscal, per the central bank. That means nominal growth of around 10%. How do you see Nifty and the broader market earnings pan out this fiscal year in this context? Do you expect the correction in markets since October to continue, or is the worst behind us?

We expect net profits of the Nifty 50 Index to grow 12% in FY26 and 15% in FY27, following a modest 6.4% growth in FY25. Diversified financials, metals & mining, oil, gas & consumable fuels and telecom will provide the bulk of the incremental profits for FY26 of the Nifty 50 Index. The sector-wise trends for the broader Kotak coverage universe of almost 300 companies are very similar to the sector-wise trends for the Nifty 50 Index. We estimate that the metals & mining sector will account for 22% and 16% of the incremental profits of FY26 of the Nifty 50 Index and KIE coverage universe, respectively.

المزيد من القصص من Mint Hyderabad

Mint Hyderabad

Mint Hyderabad

Nvidia, Eli Lilly to invest $1 bn in AI lab

Nvidia Corp. plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., aiming to speed up the use of artificial intelligence (AI) in the pharmaceutical industry.

time to read

1 min

January 13, 2026

Mint Hyderabad

Shadowfax IPO to open next week

Logistics services provider Shadowfax is set to launch its ₹1,900-crore initial public offering (IPO) next week, targeting a valuation of ₹7,400 crore, people familiar with the matter said on Monday.

time to read

1 min

January 13, 2026

Mint Hyderabad

The US climate cop-out should galvanize others

America's withdrawal from the global battle against climate change is a signal for the rest of the world to unite for the greater good. The cause is vital, not the participation of the US

time to read

2 mins

January 13, 2026

Mint Hyderabad

Toyota pushes for fuel norm clarity

The government should soon come out with the final notification for the next phase of India’s Corporate Average Fuel Efficiency standards so that the industry can prepare accordingly, according to a senior Toyota Kirloskar Motor executive.

time to read

1 min

January 13, 2026

Mint Hyderabad

Food effect lifts Dec CPI inflation

India's retail inflation rose for the second successive month in December, data released by the statistics ministry on Monday showed, driven by a moderation in negative food inflation and an uptick in core inflation.

time to read

1 min

January 13, 2026

Mint Hyderabad

Mint Hyderabad

Commissions trump advice in wealth management biz

surge on rising affluence, strong economic growth, higher foreign direct investments, and the growth of the startup ecosystem.

time to read

2 mins

January 13, 2026

Mint Hyderabad

The Chinese company taking on the world's memory-chip giants

As AI demand drives prices up, CXMT beats Washington's curbs to vie with Micron and South Korean leaders

time to read

4 mins

January 13, 2026

Mint Hyderabad

HC lifts ban on Zydus cancer biosimilar till patent expiry

In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.

time to read

2 mins

January 13, 2026

Mint Hyderabad

Fix GST on capital goods to revive private investment

India faces a paradox today.

time to read

3 mins

January 13, 2026

Mint Hyderabad

Mint Hyderabad

Feeling tired? It could be too many messages

The cumulative stress of constant notifications is leaving many emotionally burnt out. Tackling it requires small, sustainable changes

time to read

4 mins

January 13, 2026

Listen

Translate

Share

-
+

Change font size